Activity of PD-1-pathway-targeted agents in patients with advanced Merkel cell carcinoma
| Drug name | Drug class | N | Number of prior systemic therapies | ORR (%) | Reference |
|---|---|---|---|---|---|
| Avelumab | Anti-PD-L1 | 88 | 1–4 | 33 | [40] |
| 29 | 0 | 65 | [53] | ||
| Nivolumab | Anti-PD-1 | 15 | 0 | 73* | [44] |
| 10 | 1–2 | 50* | |||
| Pembrolizumab | Anti-PD-1 | 26 | 0 | 56 | [35] |
*RECIST v1.1, investigator assessed